NASDAQ:LUNALuna Innovations Competitors & Alternatives

Iqvia (NYSE:IQV) and Luna Innovations (NASDAQ:LUNA) are both business services companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.

Valuation & Earnings

This table compares Iqvia and Luna Innovations' gross revenue, earnings per share and valuation.

Iqvia has higher revenue and earnings than Luna Innovations. Iqvia is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

88.6% of Iqvia shares are held by institutional investors. Comparatively, 39.8% of Luna Innovations shares are held by institutional investors. 6.0% of Iqvia shares are held by insiders. Comparatively, 11.2% of Luna Innovations shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Iqvia and Luna Innovations' net margins, return on equity and return on assets.

Volatility and Risk

Iqvia has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Iqvia and Luna Innovations, as provided by MarketBeat.com.

Iqvia currently has a consensus price target of $153.6471, suggesting a potential upside of 7.69%. Luna Innovations has a consensus price target of $8.00, suggesting a potential upside of 55.64%. Given Luna Innovations' higher probable upside, analysts clearly believe Luna Innovations is more favorable than Iqvia.

Summary

Iqvia beats Luna Innovations on 10 of the 14 factors compared between the two stocks.

Incyte (NASDAQ:INCY) and Luna Innovations (NASDAQ:LUNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Incyte and Luna Innovations, as provided by MarketBeat.com.

Incyte currently has a consensus price target of $100.65, suggesting a potential downside of 3.92%. Luna Innovations has a consensus price target of $8.00, suggesting a potential upside of 55.64%. Given Luna Innovations' higher possible upside, analysts plainly believe Luna Innovations is more favorable than Incyte.

Insider & Institutional Ownership

91.3% of Incyte shares are held by institutional investors. Comparatively, 39.8% of Luna Innovations shares are held by institutional investors. 16.1% of Incyte shares are held by company insiders. Comparatively, 11.2% of Luna Innovations shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Incyte and Luna Innovations' net margins, return on equity and return on assets.

Volatility and Risk

Incyte has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Valuation & Earnings

This table compares Incyte and Luna Innovations' revenue, earnings per share and valuation.

Incyte has higher revenue and earnings than Luna Innovations. Luna Innovations is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Summary

Incyte beats Luna Innovations on 8 of the 13 factors compared between the two stocks.

EXACT Sciences (NASDAQ:EXAS) and Luna Innovations (NASDAQ:LUNA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, valuation, profitability, institutional ownership, risk and analyst recommendations.

Valuation & Earnings

This table compares EXACT Sciences and Luna Innovations' top-line revenue, earnings per share (EPS) and valuation.

Luna Innovations has lower revenue, but higher earnings than EXACT Sciences. EXACT Sciences is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares EXACT Sciences and Luna Innovations' net margins, return on equity and return on assets.

Risk & Volatility

EXACT Sciences has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for EXACT Sciences and Luna Innovations, as reported by MarketBeat.

EXACT Sciences currently has a consensus target price of $107.3333, indicating a potential upside of 16.57%. Luna Innovations has a consensus target price of $8.00, indicating a potential upside of 55.64%. Given Luna Innovations' higher probable upside, analysts plainly believe Luna Innovations is more favorable than EXACT Sciences.

Insider and Institutional Ownership

86.9% of EXACT Sciences shares are owned by institutional investors. Comparatively, 39.8% of Luna Innovations shares are owned by institutional investors. 1.8% of EXACT Sciences shares are owned by company insiders. Comparatively, 11.2% of Luna Innovations shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Luna Innovations beats EXACT Sciences on 8 of the 14 factors compared between the two stocks.

PPD (NASDAQ:PPD) and Luna Innovations (NASDAQ:LUNA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.

Profitability

This table compares PPD and Luna Innovations' net margins, return on equity and return on assets.

Institutional and Insider Ownership

65.5% of PPD shares are held by institutional investors. Comparatively, 39.8% of Luna Innovations shares are held by institutional investors. 11.2% of Luna Innovations shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for PPD and Luna Innovations, as reported by MarketBeat.com.

PPD currently has a consensus target price of $31.1429, indicating a potential upside of 7.06%. Luna Innovations has a consensus target price of $8.00, indicating a potential upside of 55.64%. Given Luna Innovations' higher possible upside, analysts clearly believe Luna Innovations is more favorable than PPD.

Valuation and Earnings

This table compares PPD and Luna Innovations' revenue, earnings per share and valuation.

PPD has higher revenue and earnings than Luna Innovations. PPD is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Summary

PPD beats Luna Innovations on 7 of the 13 factors compared between the two stocks.

Luna Innovations (NASDAQ:LUNA) and Icon (NASDAQ:ICLR) are both business services companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.

Risk and Volatility

Luna Innovations has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500. Comparatively, Icon has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Profitability

This table compares Luna Innovations and Icon's net margins, return on equity and return on assets.

Institutional and Insider Ownership

39.8% of Luna Innovations shares are owned by institutional investors. Comparatively, 82.7% of Icon shares are owned by institutional investors. 11.2% of Luna Innovations shares are owned by company insiders. Comparatively, 44.0% of Icon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Luna Innovations and Icon, as reported by MarketBeat.com.

Luna Innovations presently has a consensus target price of $8.00, suggesting a potential upside of 55.64%. Icon has a consensus target price of $159.1818, suggesting a potential downside of 8.66%. Given Luna Innovations' stronger consensus rating and higher possible upside, equities research analysts clearly believe Luna Innovations is more favorable than Icon.

Earnings and Valuation

This table compares Luna Innovations and Icon's revenue, earnings per share (EPS) and valuation.

Icon has higher revenue and earnings than Luna Innovations. Icon is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Summary

Icon beats Luna Innovations on 10 of the 14 factors compared between the two stocks.

Charles River Laboratories Intl. (NYSE:CRL) and Luna Innovations (NASDAQ:LUNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Institutional and Insider Ownership

93.1% of Charles River Laboratories Intl. shares are owned by institutional investors. Comparatively, 39.8% of Luna Innovations shares are owned by institutional investors. 1.9% of Charles River Laboratories Intl. shares are owned by insiders. Comparatively, 11.2% of Luna Innovations shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Charles River Laboratories Intl. and Luna Innovations' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Charles River Laboratories Intl. and Luna Innovations, as reported by MarketBeat.com.

Charles River Laboratories Intl. presently has a consensus target price of $176.8333, indicating a potential downside of 2.44%. Luna Innovations has a consensus target price of $8.00, indicating a potential upside of 55.64%. Given Luna Innovations' higher possible upside, analysts plainly believe Luna Innovations is more favorable than Charles River Laboratories Intl..

Valuation and Earnings

This table compares Charles River Laboratories Intl. and Luna Innovations' revenue, earnings per share (EPS) and valuation.

Charles River Laboratories Intl. has higher revenue and earnings than Luna Innovations. Charles River Laboratories Intl. is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Charles River Laboratories Intl. has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Luna Innovations has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.

Summary

Charles River Laboratories Intl. beats Luna Innovations on 12 of the 15 factors compared between the two stocks.